Market closedNon-fractional
Dynavax/DVAX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Dynavax
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Ticker
DVAX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
EmeryVille, United States
Employees
408
Website
www.dynavax.com
Dynavax Metrics
BasicAdvanced
$1.5B
Market cap
169.56
P/E ratio
$0.07
EPS
1.28
Beta
-
Dividend rate
Price and volume
Market cap
$1.5B
Beta
1.28
Financial strength
Current ratio
15.201
Quick ratio
13.783
Long term debt to equity
40.671
Total debt to equity
41.408
Interest coverage (TTM)
-3.13%
Management effectiveness
Return on assets (TTM)
-1.35%
Return on equity (TTM)
1.56%
Valuation
Price to earnings (TTM)
169.562
Price to revenue (TTM)
6.286
Price to book
2.43
Price to tangible book (TTM)
2.43
Price to free cash flow (TTM)
28.171
Growth
Revenue change (TTM)
-63.98%
Earnings per share change (TTM)
-95.89%
3-year revenue growth (CAGR)
27.98%
3-year earnings per share growth (CAGR)
-51.01%
What the Analysts think about Dynavax
Analyst Ratings
Majority rating from 5 analysts.
Dynavax Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$51M
-8.65%
Net income
-$8.7M
-4,450.00%
Profit margin
-17.15%
-4,863.89%
Dynavax Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.03
$0.10
-
-$0.07
-
Expected
-$0.09
-$0.02
-$0.01
-$0.02
$0.07
Surprise
-132.70%
-766.67%
-
211.11%
-
Dynavax News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Dynavax stock?
Dynavax (DVAX) has a market cap of $1.5B as of July 27, 2024.
What is the P/E ratio for Dynavax stock?
The price to earnings (P/E) ratio for Dynavax (DVAX) stock is 169.56 as of July 27, 2024.
Does Dynavax stock pay dividends?
No, Dynavax (DVAX) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Dynavax dividend payment date?
Dynavax (DVAX) stock does not pay dividends to its shareholders.
What is the beta indicator for Dynavax?
Dynavax (DVAX) has a beta rating of 1.28. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Dynavax stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.